Enric Reverter1, Francisco Mesonero2, Susana Seijo1, Javier Martínez2, Juan G Abraldes1, Beatriz Peñas2, Annalisa Berzigotti1, Ramon Deulofeu3, Jaume Bosch1, Agustín Albillos2, Joan Carles García-Pagán1. 1. 1] Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain [2] Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain. 2. 1] Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain [2] Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, University of Alcalá, Madrid, Spain. 3. 1] Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain [2] Department of Biochemistry and Molecular Genetics, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Abstract
OBJECTIVES:Tetrahydrobiopterin (BH4), a cofactor of nitric oxide synthase, might have a role in the treatment of portal hypertension (PHT) as its administration improves endothelial nitric oxide generation and hepatic endothelial dysfunction, and reduces portal pressure in experimental models of cirrhosis. Sapropterin is an oral synthetic analogue of BH4 recently approved for the treatment of phenylketonuria. This study evaluated the safety and effects of sapropterin on hepatic and systemic hemodynamics in patients with cirrhosis and PHT. METHODS:Forty patients with cirrhosis and PHT (hepatic venous pressure gradient (HVPG) ≥10 mm Hg) were randomly allocated to receive sapropterin (n=19) for 2 weeks (5 mg/kg/day increased to 10 at day 8) or placebo (n=21) in a double-blind multicenter clinical trial. Randomization was stratified according to concomitant treatment with β-adrenergic blockers. We studied at baseline and post-treatment splanchnic (HVPG and hepatic blood flow (HBF)) and systemic hemodynamics, endothelial dysfunction and oxidative stress markers (von Willebrand factor and malondialdehyde), liver function tests, and safety variables. RESULTS:HVPG was not modified by either sapropterin (16.0±4.4 vs. 15.8±4.7 mm Hg) or placebo (16.0±4.6 vs. 15.5±4.9 mm Hg). HBF, systemic hemodynamics, endothelial dysfunction markers, and liver function tests remained unchanged. Sapropterin was well tolerated (no patient required dose adjustment or withdrawal), and adverse events were mild and similar between groups. CONCLUSIONS:Sapropterin, an oral synthetic analogue of BH4, at the used dose did not reduce portal pressure in patients with cirrhosis. Sapropterin was safe and no serious adverse effects or deleterious systemic hemodynamic effects were observed.
RCT Entities:
OBJECTIVES:Tetrahydrobiopterin (BH4), a cofactor of nitric oxide synthase, might have a role in the treatment of portal hypertension (PHT) as its administration improves endothelial nitric oxide generation and hepatic endothelial dysfunction, and reduces portal pressure in experimental models of cirrhosis. Sapropterin is an oral synthetic analogue of BH4 recently approved for the treatment of phenylketonuria. This study evaluated the safety and effects of sapropterin on hepatic and systemic hemodynamics in patients with cirrhosis and PHT. METHODS: Forty patients with cirrhosis and PHT (hepatic venous pressure gradient (HVPG) ≥10 mm Hg) were randomly allocated to receive sapropterin (n=19) for 2 weeks (5 mg/kg/day increased to 10 at day 8) or placebo (n=21) in a double-blind multicenter clinical trial. Randomization was stratified according to concomitant treatment with β-adrenergic blockers. We studied at baseline and post-treatment splanchnic (HVPG and hepatic blood flow (HBF)) and systemic hemodynamics, endothelial dysfunction and oxidative stress markers (von Willebrand factor and malondialdehyde), liver function tests, and safety variables. RESULTS: HVPG was not modified by either sapropterin (16.0±4.4 vs. 15.8±4.7 mm Hg) or placebo (16.0±4.6 vs. 15.5±4.9 mm Hg). HBF, systemic hemodynamics, endothelial dysfunction markers, and liver function tests remained unchanged. Sapropterin was well tolerated (no patient required dose adjustment or withdrawal), and adverse events were mild and similar between groups. CONCLUSIONS:Sapropterin, an oral synthetic analogue of BH4, at the used dose did not reduce portal pressure in patients with cirrhosis. Sapropterin was safe and no serious adverse effects or deleterious systemic hemodynamic effects were observed.
Authors: A Albillos; J L Lledó; I Rossi; M Pérez-Páramo; M J Tabuenca; R Bañares; J Iborra; A Garrido; P Escartín; J Bosch Journal: Gastroenterology Date: 1995-10 Impact factor: 22.682
Authors: Stefanie Keil; Karen Anjema; Francjan J van Spronsen; Nilo Lambruschini; Alberto Burlina; Amaya Bélanger-Quintana; Maria L Couce; Francois Feillet; Roberto Cerone; Amelie S Lotz-Havla; Ania C Muntau; Annet M Bosch; Concetta A P Meli; Thierry Billette de Villemeur; Ilse Kern; Enrica Riva; Marcello Giovannini; Lena Damaj; Vincenzo Leuzzi; Nenad Blau Journal: Pediatrics Date: 2013-05-20 Impact factor: 7.124
Authors: Colin Cunnington; Tim Van Assche; Cheerag Shirodaria; Ilias Kylintireas; Alistair C Lindsay; Justin M Lee; Charalambos Antoniades; Marios Margaritis; Regent Lee; Ruha Cerrato; Mark J Crabtree; Jane M Francis; Rana Sayeed; Chandi Ratnatunga; Ravi Pillai; Robin P Choudhury; Stefan Neubauer; Keith M Channon Journal: Circulation Date: 2012-02-07 Impact factor: 29.690
Authors: An L Moens; Elizabeth A Ketner; Eiki Takimoto; Tim S Schmidt; Charles A O'Neill; Michael S Wolin; Nicholas J Alp; Keith M Channon; David A Kass Journal: J Mol Cell Cardiol Date: 2011-05-30 Impact factor: 5.000
Authors: Christophe A Wyss; Pascal Koepfli; Mehdi Namdar; Patrick T Siegrist; Thomas F Luscher; Paolo G Camici; Philipp A Kaufmann Journal: Eur J Nucl Med Mol Imaging Date: 2004-07-31 Impact factor: 9.236